#17

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Wayne J. Dustman

Type Name of Person Signing Certificate

[signature] January 15, 2002

Signature Date

#17

Attorney Docket No. : P31251C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Craig et al.	January 15, 2002
Serial No.:	09/469,902	Group Art Unit No.: 1625
Filed:	December 22, 1999	Examiner: C. Chang
For:	NOVEL COMPOUND	

Assistant Commissioner for Patents
Washington, D.C. 20231
Total pages 16
Fax: 703-872-9305

COMMUNICATION REQUESTING

WITHDRAWAL OF NOTICE OF ABANDONMENT

Sir:

This Communication is in response to a Notice of Abandonment mailed December 28, 2001 (copy enclosed), for Applicants' failure to respond to an Office Action mailed June 1, 2001. Applicants respectfully request that the Notice of Abandonment be withdrawn since it is not their intention to abandon this application. Indeed, a response was made to the Office Action.

As evidence of Applicants' response, enclosed is the following documentation:

(1) a copy of the Response to the Office Action;
(2) a transmittal letter requesting a three month extension of time;
(3) a Notice of Appeal to the Board of Appeals; and
(4) a copy of the postcard date stamped by the U.S.P.T.O. mailroom on January 3, 2002, indicating that items (1)-(3) were received.

Serial No.: 09/469,902
Filed: December 22, 1999

Applicants wish to acknowledge and thank the Examiner for the courtesy extended the undersigned attorney during a telephonic conversation on or about January 10, 2002. During this conversation, the Examiner suggested ways to respond to this unavoidable abandonment.

Applicants note that the returned postcard was noticeably yellowed, perhaps indicating that the response went through a decontamination procedure before being received by the PTO. It is applicants' understanding that decontamination procedures are being used on correspondence being sent to Government Agencies, including the PTO. A decontamination step could explain the unusual delay between the time applicants mailed the response and the time the PTO acknowledged receipt.

Based upon the foregoing documents and explanation, Applicants respectfully request that the Notice of Abandonment be withdrawn and that prosecution on the merits be resumed. Applicants assert that they fully responded to the Office Action, therefore, this case should not have been abandoned. Applicants request that the Examiner respond to this Communication as soon as possible so that prosecution on the merits may continue expeditiously. The Commissioner is hereby authorized to charge any fees, or credit any overpayment, incurred by this request to Deposit Account No. 19-2570.

Respectfully submitted,

Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610) 270-5090
n:\wjd\ptoltrs\P32151C1petrev.doc

CERTIFICATE OF MAILING
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON
December 3, 2001
Philip J. Furmanchuk
ATTORNEY FOR APPLICANT
December 3, 2001
DATE

Attorney Docket Number: P32151C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Craig et al.	December 3, 2001
Serial No.:	09/469,902	Group Art Unit No.: 1625
Filed:	December 22, 1999	Examiner: C. Chang
For:	NOVEL COMPOUND	

Assistant Commissioner for Patents
Box AF
Washington, D.C. 20231

AMENDMENT AFTER FINAL REJECTION

In response to the Examiner's Office Action mailed June 1, 2001, having a three month shortened statutory period for response, please enter the following amendments and remarks into the record. Also enclosed herewith is a petition for a three month extension of the shortened statutory period set by the Examiner and authorization to charge the required fee to the indicated deposit account. Also enclosed herewith is a Notice of Appeal to the Board of Patent Appeals and Interferences and authorization to charge the required fee to the indicated deposit account.

Please amend the application as follows.

Delete all of the pending claims in the application (specifically claims 114 to 154).

Add claims 155 to 203 as follows.

155. Paroxetine methanesulfonate having *inter alia* the following characteristic IR peaks: 1603, 1513, 1194, 1045, 946, 830, 776, 601, 554, and 539 ± 4 cm-1; and the following characteristic XRD peaks: 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2, and 31.6 ±0.2 degrees 2 theta.

156. Paroxetine methanesulfonate having *inter alia* the following characteristic XRD peaks: 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2, and 31.6 ±0.2 degrees 2 theta.

157. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4 cm-1.

158. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 155.

159. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 156.

160. A pharmaceutical composition comprising a compound according to claim 155 and a pharmaceutically acceptable carrier.

161. A pharmaceutical composition comprising a compound according to claim 156 and a pharmaceutically acceptable carrier.

162. A composition according to claim 160 in which the carrier comprises a binder.

163. A composition according to claim 160 in which the carrier comprises a colouring agent.

164. A composition according to claim 160 in which the carrier comprises a flavouring agent.

165. A composition according to claim 160 in which the carrier comprises a preservative.

166. A composition according to claim 160 adapted for oral administration.

167. A composition according to claim 166 which is a tablet or capsule.

168. A composition according to claim 167 which is a modified oval shaped tablet.

169. A composition according to claim 160 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

170. A composition according to claim 161 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

171. A pharmaceutical composition adapted for oral administration comprising per unit dose 10, 12.5, 15, 20, 25, 30 or 40 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4 cm^{-1}, and a pharmaceutically acceptable carrier.

172. A pharmaceutical composition adapted for oral administration comprising per unit dose 10 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

173. A pharmaceutical composition adapted for oral administration comprising per unit dose 20 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

174. A pharmaceutical composition adapted for oral administration comprising per unit dose 30 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

175. A pharmaceutical composition adapted for oral administration comprising per unit dose 40 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

176. A pharmaceutical composition adapted for oral administration comprising per unit dose 12.5 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

177. A pharmaceutical composition adapted for oral administration comprising per unit dose 15 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

178. A pharmaceutical composition adapted for oral administration comprising per unit dose 25 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

179. A pharmaceutical composition adapted for oral administration comprising per unit dose 50 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

180. Paroxetine methanesulfonate having *inter alia* the following characteristic IR peaks: 1603, 1513, 1194, 1045, 946, 830, 776, 601, 554 and 539 cm-1; and the following characteristic XRD peaks: 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2 and 31.6.

181. Paroxetine methanesulfonate having *inter alia* the following characteristic XRD peaks: 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2 and 31.6.

182. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate in crystalline form having the

following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554 and 539 cm-1.

183. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 180.

184. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 181.

185. A pharmaceutical composition comprising a compound according to claim 180 and a pharmaceutically acceptable carrier.

186. A pharmaceutical composition comprising a compound according to claim 181 and a pharmaceutically acceptable carrier.

187. A composition according to claim 180 in which the carrier comprises a binder.

188. A composition according to claim 180 in which the carrier comprises a colouring agent.

189. A composition according to claim 180 in which the carrier comprises a flavouring agent.

190. A composition according to claim 180 in which the carrier comprises a preservative.

191. A composition according to claim 180 adapted for oral administration.

192. A composition according to claim 191 which is a tablet or capsule.

193. A composition according to claim 192 which is a modified oval shaped tablet.

194. A composition according to claim 180 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

195. A composition according to claim 181 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

196. A pharmaceutical composition adapted for oral administration comprising per unit dose 10 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

197. A pharmaceutical composition adapted for oral administration comprising per unit dose 20 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

198. A pharmaceutical composition adapted for oral administration comprising per unit dose 30 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

199. A pharmaceutical composition adapted for oral administration comprising per unit dose 40 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

200. A pharmaceutical composition adapted for oral administration comprising per unit dose 12.5 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

201. A pharmaceutical composition adapted for oral administration comprising per unit dose 15 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

202. A pharmaceutical composition adapted for oral administration comprising per unit dose 25 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

203. A pharmaceutical composition adapted for oral administration comprising per unit dose 50 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

REMARKS

Claims 114 to 154 are pending in the application. Claims 115, 126-134, 136 and 147 to 154 are allowed. Claims 114 and 135 are rejected under the judicially created doctrine of obviousness-type double patenting. Claims 116 to 125 and 137 to 146 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form. Applicants respectfully request withdrawal of the outstanding rejections for the reasons set forth herein.

Entry of applicants' proposed amendments after final rejection is respectfully requested because said amendments are believed to eliminate the grounds for rejection under the judicially created doctrine of obviousness-type double patenting thereby placing the application in a condition for allowance (MPEP 714.12).

I. The Rejection Under the Judicially Created Doctrine of Obviousness-Type Double Patenting.

Claims 114 and 135 are rejected over claims 1 or 3 of U.S. Patent No. 6,063,927. Although the conflicting claims are not identical, they are not considered patentably distinct from each other because overlapping subject matter is claimed. Office Action dated June 1, 2001.

In response to the double patenting rejection, claims 114 and 135 have been deleted and replaced by newly added claims 155, 156, 180 and 181. The remaining claims have been amended to depend on the newly added claims. Whereas claims 1 and 3 of U.S. Patent No. 6,063,927 recite IR data alone, newly added claims 155, 156, 180 and 181 all recite XRD (X-ray diffraction) peaks alone or in combination with IR data. Accordingly, the claims are different in their recitations, and the Examiner is respectfully requested to reconsider and withdraw the subject rejection.

Applicants submit that the rejection has been addressed and that the claims, as amended, are allowable. Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned attorney at the number indicated below.

Respectfully submitted,



Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610) 270-5090

n:\wjd\ptoltrs\32151C1AF.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

This amendment deletes all of the previous claims and adds a new set of claims. As such, a marked up version of previous claims is not required.

CERTIFICATE OF MAILING
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON December 3, 2001

ATTORNEY FOR APPLICANT

December 3, 2001
DATE

Attorney Docket No. P32151C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Craig et al.	December 3, 2001	
Serial No.:	09/469,902	Group Art Unit No.:	1625
Filed:	December 22, 1999	Examiner:	C. Chang
For:	Novel Compound		

Assistant Commissioner for Patents
Box AF
Washington, D.C. 20231

NOTICE OF APPEAL FROM THE PRIMARY EXAMINER TO THE BOARD OF APPEALS

Applicant hereby appeals to the Board from the decision of the Primary Examiner mailed June 1, 2001 finally rejecting claims 114 and 135.

Please charge the fee of $320.00 to Deposit Account No. 19-2570.

Please charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this paper, or credit any overpayment, to Deposit Account No. 19-2570. A copy of this Notice is enclosed.

Respectfully submitted,

Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610)270-5090

DOCKET No. P37,512C1 Date Mailed 12/3/01 Atty/Secy WSD/

MAILING: CERTIFICATE/ EXPRESS MAIL # _____

U.S. Serial No. .: 09/469,902 Filing Date: 12.22.99

Int'l App. No.: _____ Int'l Filing Date: _____

RECEIPT IS ACKNOWLEDGED FOR THE FOLLOWING:

- ☐ Appln. Trans. (+ 1 copy) for: ☐ Provisional ☐ CIP ☐ Statement to Support Filing
- ☐ Utility/Continuation ☐ CPA ☐ RCE ☐ Divisional
- ☐ Specification ____ pages ☐ Abstract ___ pgs
- ☐ Dec. & Power of Atty ___ pages ( )
- ☐ Drawings ____ Sheet(s)/Figs____ to ___
- ☐ Assignment ___ pages & Recordation Cover Sheet
- ☐ Trans. Ltr Natl Stage Entry (3pgs.)
- ☐ Information Disclosure Statement
- ☐ Form PTO-1449 ___ pgs. & ___ References
- ☒ ~~Amendment~~ ☐ Response 9 pages
- ☒ ~~Petition~~ for Extension of Time plus 2 copies
- ☐ Issue Fee Trans. (Part B) + 1 copy
- ☐ Copy of Notice to File Missing Parts
- ☐ Request for Nonpublication (1 pg)
- ☒ ~~Authorization~~ to Charge Dep. Acct. # 19-2570
- ☐ _____

- ☐ Copy of Notice to Comply
- ☐ Diskette
- ☐ Appeal Brief ____ pages
- ☐ Petition ___ pgs.
- ☐ Status Request
- ☐ Trans. Nat'l Stage (2nd sub)
- ☐ Resp. to Written Opinion
- ☐ Priority Document
- ☒ Notice of Appeal/Brief *
- ☐ Resp. to Rest. Req. ___ pgs.
- ☐ Req. to Correct Filing Receipt
- ☐ Copy of Filing Receipt
- ☐ Correct Defects ___ pages

* plus 1 copy

JC152 JAN 03 2002 PATENT & TRADEMARK OFFICE

CC: MM

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/469,902	12/22/1999	ANDREW SIMON CRAIG	P312S1C1	5512

20462 7590 12/28/2001

SMITHKLINE BEECHAM CORPORATION
CORPORATE INTELLECTUAL PROPERTY-US, UW2220
P. O. BOX 1539
KING OF PRUSSIA, PA 19406-0939

EXAMINER
CHANG, CELIA C

ART UNIT	PAPER NUMBER
1625	15

DATE MAILED: 12/28/2001

Please find below and/or attached an Office communication concerning this application or proceeding.

Notice of Abandonment	Application No. 09/469,902	Applicant(s) CRAIG ET AL.	
	Examiner Celia Chang	Art Unit 1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

This application is abandoned in view of:

1. ☐ Applicant's failure to timely file a proper reply to the Office letter mailed on 06/01/01.
   (a) ☐ A reply was received on _____ (with a Certificate of Mailing or Transmission dated _____), which is after the expiration of the period for reply (including a total extension of time of _____ month(s)) which expired on _____.
   (b) ☐ A proposed reply was received on _____, but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final rejection.
   (A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114).
   (c) ☐ A reply was received on _____ but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non-final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).
   (d) ☒ No reply has been received.

2. ☐ Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three months from the mailing date of the Notice of Allowance (PTOL-85).
   (a) ☐ The issue fee and publication fee, if applicable, was received on _____ (with a Certificate of Mailing or Transmission dated _____), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Notice of Allowance (PTOL-85).
   (b) ☐ The submitted fee of $_____ is insufficient. A balance of $_____ is due.
   The issue fee required by 37 CFR 1.18 is $_____. The publication fee, if required by 37 CFR 1.18(d), is $_____.
   (c) ☐ The issue fee and publication fee, if applicable, has not been received.

3. ☐ Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of Allowability (PTO-37).
   (a) ☐ Proposed corrected drawings were received on _____ (with a Certificate of Mailing or Transmission dated _____), which is after the expiration of the period for reply.
   (b) ☐ No corrected drawings have been received.

4. ☐ The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of the applicants.

5. ☐ The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application.

6. ☐ The decision by the Board of Patent Appeals and Interference rendered on _____ and because the period for seeking court review of the decision has expired and there are no allowed claims.

7. ☐ The reason(s) below:

Please confirm abandonment
Yes ☐ No ☒
Signed: [redacted]
Date: [redacted]
MUST Follow

C.L. Chang

CEILA CHANG
PRIMARY EXAMINER
GROUP 1200

Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonment under 37 CFR 1.181, should be promptly filed to minimize any negative effects on patent term.

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON December 3, 2001

ATTORNEY FOR APPLICANT

December 3, 2001

DATE

Attorney Docket No. P32151C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Craig et al.		December 3, 2001
Serial No.:	09/469,902		Group Art Unit No.: 1625
Filed:	December 22, 1999		Examiner: C. Chang
For:	Novel Compound		

TRANSMITTAL LETTER

Transmitted herewith is an Amendment in the above-identified application.

EXTENSION OF TIME PETITION

Applicants hereby petition for an extension of time for response from the date of the Examiner's action as needed, the fee being as follows:

( )	one month extension.....	$ 110
( )	two months extension.....	$ 400
(X)	three months extension.....	$ 920
( )	four months extension (not beyond statutory time period).....	$1440
( )	five months extension	$1960

Charge **$920.00** to Deposit Account No. 19-2570. Two copies of this form are enclosed.

Please charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this paper, or credit any overpayment, to Deposit Account No. 19-2570. Also, should the Patent and Trademark Office determine that the fee calculated in the above extension petition is not deemed sufficient to have this response considered as being timely filed, this constitutes a petition for extension of time for the minimum period to effect timely filing, and the Commissioner is authorized to debit any necessary fee to said deposit account.

Respectfully submitted,

Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610) 270-5090